Deaths from the two most common urologic cancers in men (prostate and bladder) and the most common urologic cancer in women (bladder cancer) have dropped since the 1990s, according to the Annual Report to the Nation on the Status of Cancer, 1975-2002, a collaboration among the National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries.
Deaths from the two most common urologic cancers in men (prostate and bladder) and the most common urologic cancer in women (bladder cancer) have dropped since the 1990s, according to the Annual Report to the Nation on the Status of Cancer, 1975-2002, a collaboration among the National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries. The report shows that observed cancer death rates from all cancers combined dropped 1.1% per year from 1993 to 2002.
Racial disparities still exist in prostate cancer, the report showed. African-American men have a 200% higher death rate from the disease than Caucasian and other non-Caucasian men.
The most notable trend in prostate cancer treatment from 1986 to 1999 was the decreasing proportion of cases that received watchful waiting, surgical or chemical castration, or hormonal deprivation therapy as primary treatment. More aggressive treatments, including newer radiation techniques, were found to be on the rise. However, African-American men were found to receive substantially less aggressive treatment than Caucasian men.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.